University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia 22908
13 studies enrolling now · 30 studies all time
What they study most
AML, AML With Mutated NPM1, ARID1A Gene Mutation, Acute Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Adoptive Cellular Immunotherapy, Advanced Solid Tumor, Advanced Solid Tumors, Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Anal Cancer, Anal Neoplasm
Studies at this site
- LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
- Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy — Recruiting now
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen — Recruiting now
- A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer — Recruiting now
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Recruiting now
- Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer — Recruiting now
- Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma — Recruiting now
- Using Aspirin to Improve Immunological Features of Ovarian Tumors — Recruiting now
- Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer — Recruiting now
- A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer — Recruiting now
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types — Recruiting now
- A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Recruiting now
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Recruiting now
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) — Running, not enrolling
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors — Running, not enrolling
- A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) — Stopped early
- Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel — Available (expanded access)
- Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation — Stopped early
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) — Running, not enrolling
- A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) — Running, not enrolling
- Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer — Completed
- A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors — Stopped early
- A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation — Stopped early
- A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies — Completed
- (VELA) Study of BLU-222 in Advanced Solid Tumors — Stopped early
- A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors — Completed
- A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer — Running, not enrolling
- Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL — Completed
- A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors — Stopped early
- A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL — Paused